BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Business

  Sarepta’s Duchenne Gene Therapy Elevidys Nabs $200M on Strong Demand

  Sarepta Therapeutics on Wednesday called the launch of the gene therapy for Duchenne muscular dystrophy “exceptional” but the company does not expect to see significant growth in the first half of 2024 due to its currently limited patient pool.

  February 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Lilly Looks to India Launch of Mounjaro in 2025: Reuters

  Eli Lilly is planning to launch its blockbuster diabetes drug Mounjaro next year in India, the world’s most populous nation, ahead of its main competitor Novo Nordisk which is eyeing an Indian launch of Wegovy in 2026.

  February 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Incannex’s Psilocybin Clears Phase II Trial in Generalized Anxiety Disorder

  Incannex Healthcare on Wednesday said its investigational psychedelic psilocybin met the primary endpoint, demonstrating it can reduce Hamilton anxiety scores by more than nine points versus placebo.

  February 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  BlossomHill Raises $100M in Series B, Focuses on Small Molecule Design

  CEO J. Jean Cui’s track record has investors flocking to BlossomHill Therapeutics, after her last company—Turning Point Therapeutics—was sold to Bristol Myers Squibb in a $4.1 billion deal.

  February 29, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Policy

  CDC Advisory Panel Backs Valneva’s Chikungunya Vaccine for Certain Groups

  On Wednesday, the CDC’s Advisory Committee on Immunization Practices voted to recommend Valneva’s chikungunya virus vaccine Ixchiq for certain high-risk patient groups.

  February 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  The gap is where the pain is: Drug pricing and patient costs

  This episode explores the drug pricing gap between consumer experience and industry norms. Join Lori and our KOLs as we explore the drivers of healthcare costs, the CBO, rebates, and overall spend in this new series.

  February 29, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Business

  Novo Holdings, Forbion Lead Financing for Orbis Medicine’s $28M Seed Round

  Denmark-based startup Orbis Medicines has launched with €26 million in seed funding in its drive to search for macrocycle drugs, with a focus on high-value oral alternatives to blockbuster biologics.

  February 29, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Policy

  FDA Action Alert: Vanda, Eyenovia and Viatris/Mapi

  The FDA will kick off March with three target action dates, including one for an insomnia treatment and another for a multiple sclerosis therapy.

  February 29, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Policy

  New ALS Treatments Face Regulatory Uncertainty

  Despite the approval of two novel therapies for this uniformly fatal neurodegenerative disease, experts say regulatory standards and expectations are still evolving.

  February 29, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• Press Release Citeline

  February 29, 2024

   · 

  1 min read